Skip to content
lifestyle.menstyle1.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
NervGen Pharma Corp.
NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study
May 26, 2026
NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study
May 26, 2026
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
May 23, 2026
NervGen Announces Proposed Public Offering of Securities
May 23, 2026
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
May 22, 2026
NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer
April 27, 2026
NervGen Pharma to Participate in the H.C. Wainwright “HCW@Home” Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
April 13, 2026
NervGen Pharma to Participate in the H.C. Wainwright “HCW@Home” Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
April 13, 2026
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
April 7, 2026
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
March 31, 2026
1
2
Next Page
→